Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02088567 · ClinicalTrials.gov registry record · NA

Amniotic Membrane in Total Knee Replacements to Reduce Scarring

A NA study of Scarring, sponsored by MiMedx Group.

Completed
Registry status
NA
Development phase
52
Enrollment target
1
Study location

NCT02088567: Completed NA study of Scarring, sponsored by MiMedx Group.

NCT02088567 is a NA study of Scarring that has completed, run by MiMedx Group. The registered enrollment target is 52 participants, below the 77-participant average among 8 other Scarring trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02088567, a NA study of Scarring, has completed, sponsored by MiMedx Group.

COMPLETED
Registry status
NA
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

The overall objective of this study is to evaluate the effectiveness of dHACM in reducing scar tissue formation in total knee replacement patients.

Conditions Studied

Interventions

  • PROCEDURE Total Knee Arthroplasty
  • OTHER Application of dHACM

Study Locations (1)

Georgia

  • Georgia Knee and Sports Medicine - Decatur

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2014-01
Est. Completion 2014-10
Phase NA
MiMedx Group

32 total trials

What the finished NCT02088567 record still lists

NCT02088567 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 77-participant average among 8 other Scarring trials with a reported enrollment target (32% lower).

The record links to 1 condition, with Scarring appearing as the primary indexed condition, and to 2 interventions - of which Total Knee Arthroplasty is the first listed.

NCT02088567 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT02088567 about?

NCT02088567 is a clinical study titled "Amniotic Membrane in Total Knee Replacements to Reduce Scarring". The overall objective of this study is to evaluate the effectiveness of dHACM in reducing scar tissue formation in total knee replacement patients.

What is the current status of trial NCT02088567?

This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2014-01. Estimated completion is 2014-10.

What conditions does trial NCT02088567 study?

This clinical trial studies the following conditions: Scarring.

What interventions are being tested in trial NCT02088567?

The interventions under investigation include: Total Knee Arthroplasty (PROCEDURE), Application of dHACM (OTHER).

Who is sponsoring clinical trial NCT02088567?

This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02088567 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Scarring

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02088567's enrollment target sits among peer trials

52 5th of 8 higher than 4 of 8 other Scarring trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Scarring trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02088567, the US trial registry maintained by the National Library of Medicine. NCT02088567 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.